Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Non-randomized, Single Ascending Doses (SAD) Study Following Single Injection in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HNC364 Injectable Suspension

NCT05523570 is registered in ClinicalTrials.gov with Guangzhou Henovcom Bioscience Co. Ltd. as lead sponsor.

NCT NCT05523570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05523570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Non-randomized, Single Ascending Doses (SAD) Study Following Single Injection in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HNC364 Injectable Suspension
Lead sponsor
Guangzhou Henovcom Bioscience Co. Ltd.
Phase
Phase 1
Overall status
Completed
Start date
August 22, 2022
Completion date
April 15, 2024
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease